JP2016519069A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519069A5 JP2016519069A5 JP2016502236A JP2016502236A JP2016519069A5 JP 2016519069 A5 JP2016519069 A5 JP 2016519069A5 JP 2016502236 A JP2016502236 A JP 2016502236A JP 2016502236 A JP2016502236 A JP 2016502236A JP 2016519069 A5 JP2016519069 A5 JP 2016519069A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- therapeutic composition
- adi
- group
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001225 therapeutic effect Effects 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 108010082340 Arginine deiminase Proteins 0.000 claims 11
- 208000024891 symptom Diseases 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 claims 1
- 108010075480 ADI PEG20 Proteins 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003700 epoxy group Chemical group 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000005462 imide group Chemical group 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000006320 pegylation Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790833P | 2013-03-15 | 2013-03-15 | |
| US61/790,833 | 2013-03-15 | ||
| PCT/US2014/026766 WO2014151982A2 (en) | 2013-03-15 | 2014-03-13 | Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519069A JP2016519069A (ja) | 2016-06-30 |
| JP2016519069A5 true JP2016519069A5 (https=) | 2017-04-13 |
| JP6382934B2 JP6382934B2 (ja) | 2018-08-29 |
Family
ID=51581665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502236A Active JP6382934B2 (ja) | 2013-03-15 | 2014-03-13 | 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対して低減された交差反応性を有するアルギニンデイミナーゼ |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11235037B2 (https=) |
| EP (2) | EP3744341A1 (https=) |
| JP (1) | JP6382934B2 (https=) |
| KR (2) | KR102455753B1 (https=) |
| CN (1) | CN105188739B (https=) |
| AU (1) | AU2014236653B2 (https=) |
| BR (1) | BR112015021483A2 (https=) |
| CA (1) | CA2901795C (https=) |
| ES (1) | ES2805360T3 (https=) |
| RU (1) | RU2015141932A (https=) |
| SG (1) | SG11201507354QA (https=) |
| WO (1) | WO2014151982A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3782653B1 (en) | 2012-04-04 | 2025-03-19 | Polaris Group | Composition comprising pegylated arginine deiminase |
| EP3744341A1 (en) | 2013-03-15 | 2020-12-02 | TDW Group | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment |
| KR102523031B1 (ko) * | 2014-03-18 | 2023-04-19 | 티디더블유 그룹 | 조작된 키메라성 페길화된 adi 및 사용 방법 |
| US9938355B2 (en) | 2014-07-08 | 2018-04-10 | Tdw Group | Antibodies to argininosuccinate synthase and related methods |
| JP6782230B2 (ja) * | 2014-09-16 | 2020-11-11 | ティーディーダブリュー グループ | 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対する交差反応性が低減したアルギニンデイミナーゼ |
| TWI699210B (zh) * | 2015-03-18 | 2020-07-21 | 開曼群島商瑞華藥業集團 | 工程化之嵌合聚乙二醇化ａｄｉ及使用方法 |
| TWI847958B (zh) | 2016-07-05 | 2024-07-11 | 英屬開曼群島商北極星藥業集團股份有限公司 | 用精胺酸耗盡劑進行之組合癌症免疫療法 |
| TWI784982B (zh) | 2016-11-02 | 2022-12-01 | 開曼群島商北極星藥業集團股份有限公司 | 聚乙二醇化精胺酸脫亞胺酶之調配物 |
| WO2018167780A1 (en) * | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
| TWI911136B (zh) * | 2017-03-29 | 2026-01-11 | 開曼群島商北極星藥業集團股份有限公司 | 蛋白質結合物 |
| CN108324951B (zh) * | 2018-04-16 | 2021-05-25 | 薛剑峰 | 一种精氨酸脱亚胺酶注射剂及其制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| JP2900279B2 (ja) | 1989-08-02 | 1999-06-02 | 株式会社ジャパンエナジー | 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤 |
| US5804183A (en) | 1997-01-31 | 1998-09-08 | Enzon, Inc. | Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US6635462B1 (en) * | 1997-05-12 | 2003-10-21 | Phoenix Pharmacologies, Inc. | Mutated form of arginine deiminase |
| US6180387B1 (en) | 1997-08-11 | 2001-01-30 | Smithkline Beecham Corporation | Arginine deiminase |
| IT1298918B1 (it) | 1998-02-20 | 2000-02-07 | Mendes Srl | Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche |
| WO2002009741A1 (en) * | 2000-07-27 | 2002-02-07 | Angiolab, Inc. | The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis |
| WO2002044360A2 (en) | 2000-11-28 | 2002-06-06 | Phoenix Pharmacologics, Inc. | Modified arginine deiminase |
| US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| AU2003282883B2 (en) * | 2002-11-18 | 2008-12-04 | Polaris Group | Methods for inhibiting viral replication in vivo |
| WO2004097051A2 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing aml and mds differential gene expression |
| WO2005052145A2 (en) | 2003-10-07 | 2005-06-09 | University Of Florida | Recombinant alkaliizing bacteria |
| CN101002945B (zh) | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
| WO2009006590A2 (en) | 2007-07-04 | 2009-01-08 | Dr. Reddy's Laboratories Ltd. | Docetaxel process and polymorphs |
| US20090238813A1 (en) * | 2007-12-28 | 2009-09-24 | Board Of Regents, The University Of Texas System | Compositions And Methods For Engineered Human Arginine Deiminases |
| WO2010083312A2 (en) | 2009-01-14 | 2010-07-22 | The Trustees Of The University Of Pennsylvania | Micro-rna biomarker in cancer |
| WO2011053871A2 (en) * | 2009-10-30 | 2011-05-05 | Life Technologies Corporation | Multi-primer assay for mycoplasma detection |
| WO2011151704A2 (en) | 2010-06-02 | 2011-12-08 | Fresenius Kabi Oncology Ltd. | Stable pharmaceutical compositions of rapamycin esters |
| WO2012075173A2 (en) | 2010-12-01 | 2012-06-07 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
| PL394618A1 (pl) | 2011-04-19 | 2012-10-22 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
| FR2978416B1 (fr) | 2011-07-26 | 2013-11-29 | Decathlon Sa | Vehicule, par exemple du type trottinette, avec systeme de repliage |
| US8663967B2 (en) * | 2011-08-22 | 2014-03-04 | Jiangsu T-Mab Biopharma Co., Ltd. | Arginine deiminase mutant and preparation and application thereof |
| EP3782653B1 (en) | 2012-04-04 | 2025-03-19 | Polaris Group | Composition comprising pegylated arginine deiminase |
| EP3744341A1 (en) | 2013-03-15 | 2020-12-02 | TDW Group | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment |
| KR102523031B1 (ko) | 2014-03-18 | 2023-04-19 | 티디더블유 그룹 | 조작된 키메라성 페길화된 adi 및 사용 방법 |
| JP6782230B2 (ja) | 2014-09-16 | 2020-11-11 | ティーディーダブリュー グループ | 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対する交差反応性が低減したアルギニンデイミナーゼ |
-
2014
- 2014-03-13 EP EP20172604.9A patent/EP3744341A1/en active Pending
- 2014-03-13 RU RU2015141932A patent/RU2015141932A/ru not_active Application Discontinuation
- 2014-03-13 CN CN201480026318.5A patent/CN105188739B/zh active Active
- 2014-03-13 KR KR1020217016900A patent/KR102455753B1/ko active Active
- 2014-03-13 BR BR112015021483A patent/BR112015021483A2/pt not_active Application Discontinuation
- 2014-03-13 AU AU2014236653A patent/AU2014236653B2/en active Active
- 2014-03-13 KR KR1020157024832A patent/KR102263038B1/ko active Active
- 2014-03-13 CA CA2901795A patent/CA2901795C/en active Active
- 2014-03-13 ES ES14769340T patent/ES2805360T3/es active Active
- 2014-03-13 SG SG11201507354QA patent/SG11201507354QA/en unknown
- 2014-03-13 JP JP2016502236A patent/JP6382934B2/ja active Active
- 2014-03-13 EP EP14769340.2A patent/EP2968482B1/en active Active
- 2014-03-13 WO PCT/US2014/026766 patent/WO2014151982A2/en not_active Ceased
- 2014-03-14 US US14/214,040 patent/US11235037B2/en active Active
-
2021
- 2021-12-20 US US17/556,361 patent/US20220105160A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519069A5 (https=) | ||
| RU2015141932A (ru) | Аргининдеиминаза с пониженной перекрестной реактивностью к антителам adi-peg 20 для лечения рака | |
| JP2017529366A5 (https=) | ||
| Schepis et al. | State-of-the-art and upcoming innovations in pancreatic cancer care: a step forward to precision medicine | |
| Li et al. | Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma | |
| Bagnato et al. | Role of the endothelin axis and its antagonists in the treatment of cancer | |
| Chong et al. | The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets | |
| JP2017513516A5 (https=) | ||
| Damaskos et al. | Histone deacetylase (HDAC) inhibitors: current evidence for therapeutic activities in pancreatic cancer | |
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| Singh et al. | Single agent and synergistic activity of the “first-in-class” dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma | |
| RU2011146654A (ru) | Способы лечения рака яичников с применением конъюгированного средства | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| EA200970953A1 (ru) | СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ | |
| JP2017519006A5 (https=) | ||
| JP2010524968A5 (https=) | ||
| AU2017214572A1 (en) | Glucose conjugates of triptolide, analogs and uses thereof | |
| Jiang et al. | Clinical applicability of renin-angiotensin system inhibitors in cancer treatment | |
| RU2010143715A (ru) | Терапевтическое применение новых фармацевтических препаратов, содержащих противоопухолевые лекарственные средства, связанные с гиалуроновой кислотой, в лечении неоплазий | |
| Chen et al. | A codelivery system loaded with PDL1-siRNA and sorafenib enhances the therapeutic effect of sorafenib on hepatocellular carcinoma via TAT-poly-SS-lysine modified chitosan | |
| JP2016524611A5 (https=) | ||
| Wöll et al. | Chemotherapy in gastric cancer | |
| Lv et al. | A randomised controlled phase II trial of the combination of XELOX with thalidomide for the first-line treatment of metastatic colorectal cancer | |
| JP2015505557A5 (https=) | ||
| RU2018131377A (ru) | Способ, включающий фиксированное дробное дозирование цедираниба |